NASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Price, News & Analysis $6.74 -0.10 (-1.46%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.72▼$7.2450-Day Range$3.70▼$6.8452-Week Range$3.25▼$10.45Volume1.37 million shsAverage Volume1.31 million shsMarket Capitalization$570.47 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Anavex Life Sciences alerts: Email Address Anavex Life Sciences MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside493.5% Upside$40.00 Price TargetShort InterestBearish21.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.70Based on 11 Articles This WeekInsider TradingAcquiring Shares$32,919 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.55) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.80 out of 5 starsMedical Sector239th out of 936 stocksBiological Products, Except Diagnostic Industry32nd out of 154 stocks 3.8 Analyst's Opinion Consensus RatingAnavex Life Sciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Anavex Life Sciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.79% of the outstanding shares of Anavex Life Sciences have been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently increased by 3.42%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Anavex Life Sciences is -0.83. Previous Next 2.6 News and Social Media Coverage News SentimentAnavex Life Sciences has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Anavex Life Sciences this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows15 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,919.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.55% of the stock of Anavex Life Sciences is held by institutions.Read more about Anavex Life Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.55) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -13.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -13.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anavex Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Anavex Life Sciences Stock (NASDAQ:AVXL)Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Read More AVXL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVXL Stock News HeadlinesJuly 24 at 1:13 PM | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Stock Rating Upgraded by EF Hutton Acquisition Co. IJuly 24 at 10:20 AM | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. IJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 9:43 AM | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Lifted to Strong-Buy at EF Hutton Acquisition Co. IJuly 23 at 7:08 PM | msn.comEF Hutton Initiates Coverage of Anavex Life Sciences (AVXL) with Buy RecommendationJuly 22, 2024 | markets.businessinsider.comBuy Rating on Anavex: Promising Clinical Results and Strong Financial StandingJuly 22, 2024 | msn.comCassava Alzheimer’s drug set for first Phase 3 readout by December 2024July 20, 2024 | americanbankingnews.comReviewing Apogee Therapeutics (NASDAQ:APGE) and Anavex Life Sciences (NASDAQ:AVXL)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | americanbankingnews.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Short Interest Down 14.9% in JuneJune 20, 2024 | globenewswire.comAnavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceMay 22, 2024 | finance.yahoo.comSector Update: Health Care Stocks Slightly Higher Late AfternoonMay 22, 2024 | globenewswire.comAnavex Life Sciences Announces Expansion of Leadership TeamMay 21, 2024 | finance.yahoo.comAnavex Life Sciences (NASDAQ:AVXL) Is In A Good Position To Deliver On Growth PlansMay 14, 2024 | globenewswire.comAnavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQMay 13, 2024 | prnewswire.comShareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMay 10, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)May 10, 2024 | finance.yahoo.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call TranscriptSee More Headlines Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVXL CUSIPN/A CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+485.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.04% Return on Assets-26.85% Debt Debt-to-Equity RatioN/A Current Ratio15.12 Quick Ratio15.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book3.95Miscellaneous Outstanding Shares84,640,000Free Float75,331,000Market Cap$578.09 million OptionableOptionable Beta0.63 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Christopher U. Missling M.B.A. (Age 58)M.S., Ph.D., President, CEO, Secretary & Director Comp: $828.25kMs. Sandra Boenisch CPA (Age 43)CGA, Principal Financial Officer & Treasurer Comp: $194.36kMr. Stephan Toutain M.B.A. (Age 58)M.S., Senior VP of Operations & COO Dr. Walter E. Kaufmann M.D.Chief Scientific OfficerClint TomlinsonVP of CorporateDr. Adebayo Laniyonu Ph.D.Senior Vice President of Nonclinical DevelopmentDr. Edward R Hammond M.D.M.P.H., Ph.D., Chief Medical OfficerDr. Kun Jin Ph.D.Head of BiostatisticsMr. David Goldberger R.Ph.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsBioanalytical SystemsNASDAQ:BASIGemini TherapeuticsNASDAQ:GMTXAmphastar PharmaceuticalsNASDAQ:AMPHSyndax PharmaceuticalsNASDAQ:SNDXImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 40,895 shares on 7/26/2024Ownership: 0.331%SG Americas Securities LLCBought 13,434 shares on 7/12/2024Ownership: 0.016%Fiduciary Alliance LLCBought 6,000 shares on 7/10/2024Ownership: 0.023%Peter D.O. DonhauserBought 2,835 shares on 6/14/2024Total: $10,319.40 ($3.64/share)Virtu Financial LLCBought 18,954 shares on 5/20/2024Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions AVXL Stock Analysis - Frequently Asked Questions How have AVXL shares performed this year? Anavex Life Sciences' stock was trading at $9.31 at the beginning of 2024. Since then, AVXL stock has decreased by 27.6% and is now trading at $6.74. View the best growth stocks for 2024 here. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) released its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). Who are Anavex Life Sciences' major shareholders? Top institutional investors of Anavex Life Sciences include Bank of New York Mellon Corp (0.33%), Fiduciary Alliance LLC (0.02%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Steffen Thomas and Peter DO Donhauser. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX) and Geron (GERN). This page (NASDAQ:AVXL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.